AbbVie. has been granted a patent for injectable compositions aimed at enhancing skin hydration, elasticity, and texture. The method involves administering a crosslinked hyaluronic acid gel, primarily composed of low molecular weight hyaluronic acid, to improve skin smoothness on the face, neck, or décolletage. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Injectable hyaluronic acid compositions for skin improvement
The granted patent US12011500B2 outlines a method for enhancing skin smoothness, hydration, and elasticity on the face, neck, or décolletage through the administration of a specific hyaluronic acid (HA) gel. The method involves intradermal injections of a composition that features a crosslinked HA matrix, predominantly composed of low molecular weight HA material (over 50% by weight) with a molecular weight ranging from 400,000 Da to 800,000 Da. The HA concentration in the gel is specified to be between 10 mg/g and 12 mg/g, and the crosslinking is achieved using agents such as 1,4-butanediol diglycidyl ether. Notably, the composition is devoid of vitamins, and the injections are to be spaced between 2 mm to 20 mm apart, with various claims specifying narrower ranges.
Additionally, the patent includes methods for treating superficial skin depressions using a similar HA gel composition. The claims emphasize the importance of the low molecular weight HA content, with options for higher percentages (70% to 90% by weight) and the inclusion of high molecular weight HA materials. The injections are also specified to be intradermal, and the methods aim to provide sustained improvements in skin smoothness for periods ranging from at least three to six months post-treatment. The patent details various parameters for injection spacing and HA composition, underscoring the method's potential applications in cosmetic dermatology.
To know more about GlobalData’s detailed insights on AbbVie, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
